Compare HCA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCA | REGN |
|---|---|---|
| Founded | 1968 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.1B | 73.9B |
| IPO Year | N/A | 1991 |
| Metric | HCA | REGN |
|---|---|---|
| Price | $470.73 | $809.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 24 |
| Target Price | $472.12 | ★ $798.42 |
| AVG Volume (30 Days) | ★ 1.1M | 824.3K |
| Earning Date | 01-27-2026 | 01-30-2026 |
| Dividend Yield | ★ 0.61% | 0.43% |
| EPS Growth | ★ 15.74 | 2.88 |
| EPS | 25.82 | ★ 41.59 |
| Revenue | ★ $74,372,000,000.00 | $14,247,800,000.00 |
| Revenue This Year | $8.35 | $1.99 |
| Revenue Next Year | $4.47 | $6.68 |
| P/E Ratio | ★ $18.23 | $19.53 |
| Revenue Growth | ★ 6.82 | 2.89 |
| 52 Week Low | $295.00 | $476.49 |
| 52 Week High | $520.00 | $814.10 |
| Indicator | HCA | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 68.64 |
| Support Level | $462.77 | $753.20 |
| Resistance Level | $488.61 | $779.75 |
| Average True Range (ATR) | 9.41 | 15.80 |
| MACD | -0.19 | -0.51 |
| Stochastic Oscillator | 34.68 | 93.24 |
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).